Literature DB >> 12839878

Properties of NO-activated guanylyl cyclases expressed in cells.

Barry J Gibb1, Victoria Wykes, John Garthwaite.   

Abstract

1. Physiological nitric oxide (NO) signal transduction occurs through activation of guanylyl cyclase (GC)-coupled receptors, resulting in cGMP accumulation. There are five possible receptors: four heterodimers (alpha1beta1, alpha2beta1, alpha1beta2, alpha2beta2) and a presumed homodimer (nubeta2). The present study investigated the kinetic and pharmacological properties of all these putative receptors expressed in COS-7 (or HeLa) cells. 2. All exhibited NO-activated GC activity, that of alpha1beta1 and alpha2beta1 being much higher than that of the beta2-containing heterodimers or nubeta2. All were highly sensitive NO detectors. Using clamped NO concentrations, EC(50) values were 1 nM for alpha1beta1 and 2 nM for alpha2beta1. With alpha1beta2, alpha2beta2 and nubeta2, the EC(50) was estimated to be lower, about 8 nM. 3. All the GCs displayed a marked desensitising profile of activity. Consistent with this property, the concentration-response curves were bell-shaped, particularly those of the beta2 heterodimers and nubeta2. 4. Confocal microscopy of cells transfected with the fluorescently tagged beta2 subunit suggested targeting to the endoplasmic reticulum through its isoprenylation sequence, but no associated particulate GC activity was detected. 5. The NO-stimulated GC activity of all heterodimers and nubeta2 was inhibited by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one and, except for nubeta2, was enhanced by the allosteric activator YC-1. 6. It is concluded that all the four possible heterodimers, as well as the putative nubeta2 homodimer, can function as high-affinity GC-coupled NO receptors when expressed in cells. They exhibit differences in NO potency, maximal GC activity, desensitisation kinetics and possibly subcellular location but, except for nubeta2, cannot be differentiated using existing pharmacological agents.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12839878      PMCID: PMC1573914          DOI: 10.1038/sj.bjp.0705318

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  28 in total

1.  A point-mutated guanylyl cyclase with features of the YC-1-stimulated enzyme: implications for the YC-1 binding site?

Authors:  A Friebe; M Russwurm; E Mergia; D Koesling
Journal:  Biochemistry       Date:  1999-11-16       Impact factor: 3.162

2.  Sub-second kinetics of the nitric oxide receptor, soluble guanylyl cyclase, in intact cerebellar cells.

Authors:  T C Bellamy; J Garthwaite
Journal:  J Biol Chem       Date:  2000-11-09       Impact factor: 5.157

3.  Guanylyl cyclase/PSD-95 interaction: targeting of the nitric oxide-sensitive alpha2beta1 guanylyl cyclase to synaptic membranes.

Authors:  M Russwurm; N Wittau; D Koesling
Journal:  J Biol Chem       Date:  2001-09-25       Impact factor: 5.157

4.  Subunits of the nitric oxide receptor, soluble guanylyl cyclase, expressed in rat brain.

Authors:  B J Gibb; J Garthwaite
Journal:  Eur J Neurosci       Date:  2001-02       Impact factor: 3.386

5.  Nitric oxide activates the beta 2 subunit of soluble guanylyl cyclase in the absence of a second subunit.

Authors:  M Koglin; K Vehse; L Budaeus; H Scholz; S Behrends
Journal:  J Biol Chem       Date:  2001-06-13       Impact factor: 5.157

6.  The shaping of nitric oxide signals by a cellular sink.

Authors:  C Griffiths; J Garthwaite
Journal:  J Physiol       Date:  2001-11-01       Impact factor: 5.182

7.  Membrane localization of cyclic nucleotide phosphodiesterase 3 (PDE3). Two N-terminal domains are required for the efficient targeting to, and association of, PDE3 with endoplasmic reticulum.

Authors:  Y Shakur; K Takeda; Y Kenan; Z X Yu; G Rena; D Brandt; M D Houslay; E Degerman; V J Ferrans; V C Manganiello
Journal:  J Biol Chem       Date:  2000-12-08       Impact factor: 5.157

Review 8.  Guanylate cyclase and the .NO/cGMP signaling pathway.

Authors:  J W Denninger; M A Marletta
Journal:  Biochim Biophys Acta       Date:  1999-05-05

9.  Molecular mechanisms involved in the synergistic activation of soluble guanylyl cyclase by YC-1 and nitric oxide in endothelial cells.

Authors:  K Schmidt; A Schrammel; D Koesling; B Mayer
Journal:  Mol Pharmacol       Date:  2001-02       Impact factor: 4.436

10.  Rapid nitric oxide-induced desensitization of the cGMP response is caused by increased activity of phosphodiesterase type 5 paralleled by phosphorylation of the enzyme.

Authors:  F Mullershausen; M Russwurm; W J Thompson; L Liu; D Koesling; A Friebe
Journal:  J Cell Biol       Date:  2001-10-15       Impact factor: 10.539

View more
  18 in total

1.  In vivo reconstitution of the negative feedback in nitric oxide/cGMP signaling: role of phosphodiesterase type 5 phosphorylation.

Authors:  Florian Mullershausen; Michael Russwurm; Doris Koesling; Andreas Friebe
Journal:  Mol Biol Cell       Date:  2004-07-07       Impact factor: 4.138

2.  Assessing the physiological concentration and targets of nitric oxide in brain tissue.

Authors:  Catherine N Hall; David Attwell
Journal:  J Physiol       Date:  2008-06-05       Impact factor: 5.182

3.  Soluble Guanylyl Cyclases in Invertebrates: Targets for NO and O(2).

Authors:  David B Morton; Anke Vermehren
Journal:  Adv Exp Biol       Date:  2007

Review 4.  New insight into the functioning of nitric oxide-receptive guanylyl cyclase: physiological and pharmacological implications.

Authors:  John Garthwaite
Journal:  Mol Cell Biochem       Date:  2009-12-11       Impact factor: 3.396

Review 5.  NO as a multimodal transmitter in the brain: discovery and current status.

Authors:  John Garthwaite
Journal:  Br J Pharmacol       Date:  2018-12-05       Impact factor: 8.739

Review 6.  RNA splicing in regulation of nitric oxide receptor soluble guanylyl cyclase.

Authors:  Iraida G Sharina; Gilbert J Cote; Emil Martin; Marie-Francoise Doursout; Ferid Murad
Journal:  Nitric Oxide       Date:  2011-08-16       Impact factor: 4.427

7.  Localization of soluble guanylyl cyclase in the superficial dorsal horn.

Authors:  Jin-Dong Ding; Richard J Weinberg
Journal:  J Comp Neurol       Date:  2006-04-20       Impact factor: 3.215

8.  The regulation of sGC on the rat model of neuropathic pain is mediated by 5-HT1ARs and NO/cGMP pathway.

Authors:  Zifeng Xu; Bin Yang; Jianhai Zhang; Jijian Zheng
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

9.  Characterization of functional heme domains from soluble guanylate cyclase.

Authors:  David S Karow; Duohai Pan; Joseph H Davis; Sönke Behrends; Richard A Mathies; Michael A Marletta
Journal:  Biochemistry       Date:  2005-12-13       Impact factor: 3.162

10.  Heme-assisted S-nitrosation desensitizes ferric soluble guanylate cyclase to nitric oxide.

Authors:  Nathaniel B Fernhoff; Emily R Derbyshire; Eric S Underbakke; Michael A Marletta
Journal:  J Biol Chem       Date:  2012-10-23       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.